Mirador Therapeutics closed a $250 million Series B to accelerate development of precision medicines for immune diseases and signaled plans to consider an IPO later this year. The financing positions Mirador to expand clinical programs and scale CMC and commercial preparation ahead of potential public-market entry. The round underscores strong investor appetite for immunology-focused platforms; Mirador will use proceeds to advance lead candidates and broaden its discovery pipeline as it readies for larger late‑stage studies or strategic partnerships.